
OrsoBio
Developing first-in-class therapies to treat patients with metabolic disorders including diabetes, severe dyslipidemias, and more.
Employees
Enterprise value
$268—402m
Authorizing premium user...
Developing first-in-class therapies to treat patients with metabolic disorders including diabetes, severe dyslipidemias, and more.